ASHP therapeutic position statement on the appropriate use of medications in the treatment of attention-deficit/hyperactivity disorder in pediatric patients

American Journal of Health-System Pharmacy

Volumn 62, Issue 14, 2005, Pages 1502-1509

  Dopheide, Julie A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLONIDINE; DEXAMPHETAMINE; DEXEDRINE SPANSULE; DEXMETHYLPHENIDATE; GUANFACINE; METHYLIN ER; METHYLPHENIDATE; MOOD STABILIZER; PEMOLINE; PEMOLINE MAGNESIUM; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

ANOREXIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; BLOOD PRESSURE; CHILD PSYCHIATRY; CLINICAL TRIAL; CONSTIPATION; DISEASE COURSE; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG LABELING; DYSPHORIA; ELECTROCARDIOGRAM; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; INSOMNIA; IRRITABILITY; LIVER TOXICITY; MEDICAL SOCIETY; META ANALYSIS; NAUSEA; PATIENT EDUCATION; PATIENT MONITORING; PHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL CARE; RASH; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; STOMACH PAIN; SUBSTANCE ABUSE; SUDDEN DEATH; SYMPTOM; SYNCOPE; SYSTEMATIC REVIEW; TACHYCARDIA; TIC; WEIGHT GAIN; XEROSTOMIA;

EID: 22444445855     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp040600     Document Type: Review

References (34)

1. Jensen PS, Kettle L, Roper MT et al. Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. J Am head Child Adolesc Psychiatry. 1999; 38:797-804.
2. Angola A, Erkanli A, Egger HL et al. Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry. 2000; 39:975-84.
3. LeFever GB, Dawson KV, Morrow AL. The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools. Am J Public Health. 1999; 89:1359-64.
4. National Institutes of Health. Diagnosis and treatment of attention deficit hyperactivity disorder. NIH consensus statement, http://odp.od.nih.gov/ consensus/ cons/110/110_statement.htm (accessed 2005 Apr 19).
5. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000; 105:1158-70.
6. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal treatment study of children with ADHD. Arch Gen Psychiatry. 1999; 56:1073-86.
7. Greenhill LL, Pliszka S, Dulcan MK et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002; 41(2 suppl):26S-49S.
8. Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of ADHD. Clin Ther. 2003; 25:3065-83.
9. Pliszka SR, Greenhill LL, Crismon ML et al. The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part II: tactics. Attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2000; 39:920-7.
10. American Academy of Pediatrics Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001; 108:1033-44.
11. Castellanos FX, Lee PP, Sharp W et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/ hyperactivity disorder. JAMA. 2002; 288:1740-8.
12. Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V: scales assessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2003; 42:1015-37.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision. Washington, DC: American Psychiatric Press; 2000.
14. Gaub M, Carlson CL. Gender differences in ADHD: a meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry. 1997; 36:1036-45.
15. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002; 63(suppl 12):10-5.
16. Biederman J. Attention-deficit/hyperactivity disorder: a lifespan perspective. J Clin Psychiatry. 1998; 59(suppl 7):4-16.
17. Mannuzza S, Klein R, Bessler A et al. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry. 1998; 155:493-8.
18. Wilens TE, Faraone SV, Biederman J et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003; 111: 179-85.
19. Leibson CL, Katusic SK, Barbaresi WJ et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA. 2001; 285:60-6.
20. Keating GM, Figgitt DP. Dexmethylphenidate. Drugs. 2002; 62:1899-904.
21. Abikoff H, Hechtman L, Klein RG et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004; 43:802-11.
22. Pappadopulos E, Macintyre JC, Crismon ML et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry. 2003; 42:145-61.
23. Riddle MA, Kastelic EA, Frosch E. Pediatric psychopharmacology. J Child Psychol Psychiatry. 2001; 42:73-90.
24. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry. 2003; 42:886-94.
25. Connor DR, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999; 38:1551-9
26. Zito JM, Safer DJ, dos Reis S et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000; 283:1025-30.
27. Biederman J, Wilens T, Mick E et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces the risk for a substance use disorder. Pediatrics. 1999; 104:e20.
28. Pelham WE Jr, Wheeler T, Chronis A. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol. 1998; 27:190-205.
29. Lisska MC, Rivkees SA. Daily methylphenidate use slows the growth of children: a community based study. J Pediatr. Endocrinol Metab. 2003; 16:711-8.
30. Gross-Tsur V, Manor O, van der Meere J et al. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr. 1997; 130:670-4.
31. Sachs GS, Baldassano CF, Truman CJ et al. Comorbidity of attention deficit hyperactivity disorder with early- and late-onset bipolar disorder. Am J Psychiatry. 2000; 157:466-8.
32. Weiss MD, Weiss JR. A guide to the treatment of adults with ADHD. J Clin Psychiatry. 2004; 65(suppl 3):27-37.
33. Rappaport N, Chubinsky P. The meaning of psychotropic medications for children, adolescents, and their families. J Am Acad Child Adolesc Psychiatry. 2000; 39:1198-200.
34. Hinshaw SP, Owens EB, Wells KC et al. Family processes and treatment outcomes in the MTA: negative/ineffective parenting practices in relation to multimodal treatment. J Abnorm Child Psychol. 2000; 28:555-68.